Modern approaches to the therapy of patients with refractory/recurrent high-risk neuroblastoma: results of the expert council
Abstract
Neuroblastoma (NB) is the most common extracranial tumor in children aged 0–14 years. Modern approaches to the treatment are based on the stratification of patients into 3 risk groups. Despite the use of multimodal therapy, the prognosis for high-risk patients remains unfavorable. Tumor cells in NB in most cases express the glycolipid disialoganglioside GD2, which is considered as a target for immunotherapy. Naxitamab, a humanized anti-GD2 antibody of the IgG1 class, is one of the modern drugs widely used for immunotherapy throughout the world. Naxitamab has shown higher affinity to GD2 in vitro.
On September 9, 2022 Advisory Board was held in Moscow with the participation of experts from leading Russian federal and regional centers of oncology and an invited international expert Jaume Mora – Head of the Children’s Oncology Center of the Sant Joan de D u Children’s Hospital in Barcelona. The purpose of Advisory Board was to discuss approaches to the treatment of patients with refractory/recurrent high-risk NB in Europe and the Russian Federation and the place of immunotherapy in this treatment. Leading federal centers presented the experience of using Naxitamab due to the Expanded Access. The experts of Advisory Board made recommendations on further steps and prospects for the use of immunotherapy and chemoimmunotherapy in Russia.
About the Authors
M. B. Belogurova
Saint Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)
Russian Federation
Russian Federation
let. A, 68А Leningradskaya St., Pesochny, Saint Petersburg, 197758
S. R. Varfolomeeva
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashirskoe Shosse, Moscow, 115478
A. P. Kazantsev
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashirskoe Shosse, Moscow, 115478
I. V. Kazantsev
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
Russian Federation
Russian Federation
12 Rentgena St., Saint Petersburg, 197022
D. Yu. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Samory Mashela St., Moscow, 117997
S. A. Kuleva
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758
E. V. Kumirova
Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow
Russian Federation
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
D. V. Litvinov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Samory Mashela St., Moscow, 117997
G. B. Sagoyan
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashirskoe Shosse, Moscow, 115478
T. V. Shamanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Samory Mashela St., Moscow, 117997
References
1. Shamanskaya T.V., Andreeva N.A., Utalieva D.T., Kachanov D.Yu. GD2-targeted immunotherapy for high-risk neuroblastoma using chimeric ch14.18 antibodies. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2020;19(3):173–8. (In Russ.) doi: 10.24287/1726-1708-2020-19-3-173-188.
2. Sait S., Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17(10):889–904. doi: 10.1080/14737140.2017.1364995.
3. Cheung N.K.V., Guo H., Hu J., Tassev D.V., Cheung I.Y. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1(4):477–86. doi: 10.4161/onci.19864.
4. Lisby S., Liebenberg N., Bukrinski J., Sonderby P., Lund-Hansen T. Naxitamab, An Antibody with Distinct Complementary Determining Regions and High Binding Affinity to Disialoganglioside GD2. Pediatric Blood Cancer. 2020;67:281–2.
5. Danyelza (naxitamab-gqgk). Prescribing Information: 14. Clinical studies. Y-mAbs Therapeutics, Inc.; 25 Nov 2020.
6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03363373. Accessed 30 July 2021.
7. Morgenstern D.A., Mora J., Chan G.C., Nysom K., Bear M., Dalby L.W., Kushner B.H. Pivotal Trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB). Ann Oncol. 2020;31:1448. doi: 10.1016/j.annonc.2020.10.562.
8. Mora J., Chan G.C., Morgenstern D.A., Nysom K., Bear M., Dalby L.W., Kushner B.H. Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB). Ann Oncol. 2020;31:1448. doi: 10.1016/j.annonc.2020.10.563.
9. Kushner B.H., Cheung I.Y., Modak S., Basu E.M., Roberts S.S., Cheung N.K. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial. JAMA Oncol. 2018;4(12):1729–35. doi: 10.1001/jamaoncol.2018.4005.
10. Mora J., Chan G.C., Morgenstern D.A., Nysom K., Bear M.K., Tornøe K., Kushner B.H. Outpatient administration of naxitamab in combination with granulocyte-macrophage-colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events. Cancer Rep (Hoboken). 2022;e1627. doi: 10.1002/cnr2.1627.
Review
For citations:
Belogurova M.B., Varfolomeeva S.R., Kazantsev A.P., Kazantsev I.V., Kachanov D.Yu., Kuleva S.A., Kumirova E.V., Litvinov D.V., Sagoyan G.B., Shamanskaya T.V. Modern approaches to the therapy of patients with refractory/recurrent high-risk neuroblastoma: results of the expert council. Russian Journal of Pediatric Hematology and Oncology. 2022;9(3):124-126. (In Russ.)
Views:
498
Email this article 